2-[[(4-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}phenyl)methyl](methyl)amino]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4(1H)-pyrimidinone trifluoroacetate | 1380427-12-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[[(4-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}phenyl)methyl](methyl)amino]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4(1H)-pyrimidinone trifluoroacetate
• 英文别名: 2-[[(4-{[4-Chloro-3-(trifluoromethyl)phenyl]oxy}phenyl)methyl](methyl)amino]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4(1H)-pyrimidinone trifluoroacetate；2-[[4-[4-chloro-3-(trifluoromethyl)phenoxy]phenyl]methyl-methylamino]-5-[(1-methylpyrazol-4-yl)methyl]-1H-pyrimidin-6-one;2,2,2-trifluoroacetic acid
• CAS: 1380427-12-2
• 化学式: C₂HF₃O₂*C₂₄H₂₁ClF₃N₅O₂
• 分子量: 617.935
• InChiKey: PWGGFVHCHRUJQX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.83
• 重原子数：
  42
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  109
• 氢给体数：
  2
• 氢受体数：
  12

反应信息

• 作为产物：
  描述：

  N-[(4-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}phenyl)methyl]-N-methylguanidine 、 Dicaesio carbonate 、 methyl (2Z)-3-hydroxy-2-[(1-methyl-1H-pyrazol-4-yl)methyl]-2-propenoate 以 N-甲基吡咯烷酮 为溶剂， 反应 1.0h， 以then afforded the title compound as a white solid (13 mg, 15.1% yield)的产率得到2-[[(4-{[4-chloro-3-(trifluoromethyl)phenyl]oxy}phenyl)methyl](methyl)amino]-5-[(1-methyl-1H-pyrazol-4-yl)methyl]-4(1H)-pyrimidinone trifluoroacetate
  参考文献：
  名称：

  PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2

  摘要：

  本发明涉及一种新的化合物，其抑制Lp-PLA2活性，其制备过程，包含它们的组合物以及它们在治疗与Lp-PLA2活性相关的疾病中的应用，例如动脉粥样硬化，阿尔茨海默病和/或糖尿病黄斑水肿。

  公开号：

  US20130252963A1

文献信息

• [EN] PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP - PLA2<br/>[FR] COMPOSÉS DE PYRIMIDINONE UTILES DANS LE TRAITEMENT DE MALADIES OU D'ÉTATS PATHOLOGIQUES INDUITS PAR LA LP-PLA2
  申请人：GLAXO GROUP LTD

  公开号：WO2012076435A1

  公开（公告）日：2012-06-14

  The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema (I).

  本发明涉及抑制Lp-PLA2活性的新化合物，其制备方法，含有这些化合物的组合物以及它们在治疗与Lp-PLA2活性相关的疾病中的应用，例如动脉粥样硬化、阿尔茨海默病和/或糖尿病黄斑水肿。
• PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2
  申请人：Jin Yun

  公开号：US20130252963A1

  公开（公告）日：2013-09-26

  The present invention relates to novel compounds that inhibit Lp-PLA 2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA 2 , or example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.

  本发明涉及一种新的化合物，其抑制Lp-PLA2活性，其制备过程，包含它们的组合物以及它们在治疗与Lp-PLA2活性相关的疾病中的应用，例如动脉粥样硬化，阿尔茨海默病和/或糖尿病黄斑水肿。
• COMPOUNDS
  申请人：GLAXO GROUP LIMITED

  公开号：US20140113922A1

  公开（公告）日：2014-04-24

  The present invention relates to novel compounds that inhibit Lp-PLA 2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA 2 , for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.

  本发明涉及一种新型化合物，可以抑制Lp-PLA2活性，制备该化合物的方法，含有该化合物的组合物以及在治疗与Lp-PLA2活性相关的疾病，例如动脉粥样硬化、阿尔茨海默病和/或糖尿病黄斑水肿方面的用途。
• Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2
  申请人：Jin Yun

  公开号：US08637536B2

  公开（公告）日：2014-01-28

  The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.

  本发明涉及一种新型化合物，可抑制Lp-PLA2活性，其制备过程，包含它们的组合物以及它们在与Lp-PLA2活性相关的疾病治疗中的应用，例如动脉粥样硬化、阿尔茨海默病和/或糖尿病黄斑水肿。
• Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2
  申请人：GLAXO GROUP LIMITED

  公开号：US09174968B2

  公开（公告）日：2015-11-03

  The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease, and/or diabetic macular edema.

  本发明涉及新型化合物，其抑制Lp-PLA2活性，包括它们的制备方法、含有它们的组合物以及它们在与Lp-PLA2活性相关的疾病治疗中的应用，例如动脉粥样硬化、阿尔茨海默病和/或糖尿病黄斑水肿。